Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
Conclusions: These results suggested that canagliflozin was a cost-saving treatment option compared with dapagliflozin from the perspective of Chinese health care services providers for Chinese patients with T2DM who are inadequately controlled on metformin monotherapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Canagliflozin | China Health | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Forxiga | Health Management | Invokana | Metformin | SGLT2 Inhibitors | Sodium | Study